Revolax®

Order Revolax® Online — Compare Korean Hyaluronic Acid Dermal Filler Products

Revolax® is a highly purified, CE-marked Korean hyaluronic acid dermal filler built around three viscosity grades, Fine, Deep, and Sub-Q, covering injection depths from intradermal fine-line correction to deep subcutaneous volumization. Each Revolax® filler variant is available with or without lidocaine, giving practitioners flexibility for patient comfort and treatment protocol. Licensed professionals can order Revolax® or buy Revolax® online through Medical Spa Rx, with secure checkout and both individual-unit and wholesale ordering for clinics. Compare the full Revolax® Sub-Q, Fine, and Deep range below.

About Revolax® — Highly Purified Korean HA Fillers

Revolax® dermal filler contains hyaluronic acid, and is manufactured by Across Co., Ltd., a South Korean medical aesthetics company specializing in injectable HA technologies. The products are made under the oversight of South Korea’s Ministry of Food and Drug Safety (MFDS) and carry CE marking as a Class III medical device, reflecting compliance with recognized international quality and safety standards.

All formulations contain biodegradable, non-animal hyaluronic acid molecules, a naturally occurring glycosaminoglycan found in human connective tissue. Using proprietary purification and cross-linking technology, the HA is processed into a monophasic, cross-linked gel with uniformly distributed cross-linked and free HA, supporting smooth injection, predictable handling, and consistent clinical performance across the three-grade range [4]. That consistency matters in practice. A clinic switching between Fine, Deep, and Sub-Q syringes within the same appointment is working with the same underlying gel chemistry rather than three unrelated formulations, which simplifies both technique and patient counseling.

Why Practitioners Choose Revolax® Filler

Revolax® has established itself among aesthetic filler experts for two reasons that consistently influence procurement.

• Procurement Simplicity: A complete Fine, Deep, and Sub-Q system covers superficial, mid, and deep tissue correction from a single CE- and MFDS-approved Korean manufacturer. That lets a clinic standardize an entire injectable depth range around one brand rather than sourcing separate products for each treatment plane. Practices that buy dermal fillers across several depth categories find that consolidation simplifies inventory, training, and treatment planning at once.
• Value Without Compromise on Quality: Revolax® filler is a highly purified, monophasic, cross-linked HA filler manufactured to international standards, holding both CE certification and MFDS approval. That regulatory backing is typically associated with premium European filler pricing. Revolax® sits at a more competitive wholesale price without asking practices to compromise on purity standards, which is part of why it appears so often in procurement comparisons against higher-priced European alternatives.

About the Manufacturer

Revolax®’s manufacturer is Across Co., Ltd., a Korean specialist HA filler manufacturer that develops its purification and cross-linking process in-house rather than licensing third-party HA chemistry. Clinics that buy Korean dermal fillers often evaluate Revolax® alongside other Korean-origin brands precisely because of that vertically integrated model, which gives the company direct control over raw material sourcing, purification standards, and cross-linking consistency across batches. Manufacturing follows MFDS quality requirements, while CE certification demonstrates compliance with the European Medical Device Regulation [4].

Revolax® Product Range — Fine Filler, Deep Filler, and Revolax® Sub Q Explained

The three viscosity grades are calibrated for distinct injection depths and treatment indications, following general depth-matching principles used across HA filler selection [2].

Revolax® Fine filler has the lowest viscosity in the range, which suits superficial and intradermal placement, where a low-resistance gel integrates without displacing surrounding tissue or adding unwanted projection.

Revolax® Deep filler occupies the mid-viscosity position and is the most broadly applicable formulation, designed for mid-to-deep dermal injection across mainstream facial indications. It doubles as the Revolax® lip filler most practices stock, since the same cohesivity that holds a nasolabial fold also holds lip volume.

Revolax® Sub Q has the highest viscosity and is engineered for subcutaneous and supraperiosteal placement, providing the structural support and projection required for deep facial contouring.

Each formulation is available with or without lidocaine hydrochloride. When selecting between the two, practitioners weigh patient comfort, treatment area, and existing anesthetic protocols. Healthcare providers who purchase Revolax® online should check both the formulation and the shipping requirements, since lidocaine-containing variants carry different storage and transit conditions in some markets. Lidocaine-containing variants reduce discomfort during injection and may remove the need for additional anesthesia, while non-lidocaine formulations remain suitable for patients with amide-anesthetic sensitivities or practices that prefer topical anesthesia.

Revolax® Lip Filler and Other Treatment Areas — Indications by Grade

• Revolax® Fine: The treatment areas here are superficial, periorbital rhytides, glabellar lines and neck wrinkles, all placed intradermally to smooth the skin without adding excess volume.
• Revolax® Deep: Used for mid-to-deep facial work: marionette lines, cheek volume restoration, and the grade practitioners reach for to reduce nasolabial folds, where a cohesive gel needs to restore volume while maintaining natural movement. It is also used for vermilion border definition and body augmentation.
• Revolax® Sub-Q: Reserved for deep structural augmentation of the jawline and cheekbones, and for chin filler placement at subcutaneous or supraperiosteal depth. That is aesthetic implant-level placement, intended to improve projection, definition, and overall facial balance with longer-lasting structural support.

Revolax® Technology — Cross-Linked HA Purity Standards

Revolax® is a monophasic, cross-linked hyaluronic acid filler manufactured using butanediol diglycidyl ether (BDDE) to create stable covalent bonds between HA chains [4]. Cross-linking improves resistance to enzymatic degradation and drives gel viscosity, which determines the appropriate injection depth for each formulation. Higher cross-linking density correlates with greater cohesivity under tissue pressure, which is why the Sub-Q grade supports structural projection in ways the Fine grade is not designed to.

A defining feature of the range is its purity standard. Revolax® is a highly purified bio-degradable acid filler in which residual BDDE is reduced during manufacturing to levels intended to comply with internationally accepted safety standards [4], which minimizes localized inflammatory reactions and supports consistent injection performance. The monophasic gel structure further supports smooth integration and predictable handling during treatment. Clinics that buy HA dermal fillers and want a single high-purity supplier across multiple viscosity grades often cite this purification standard as the reason Revolax® fits that role.

Clinical longevity varies by formulation. Revolax® Fine provides roughly 6 to 9 months of correction, while Revolax® Deep and Sub-Q may maintain results for around 12 to 18 months, depending on treatment area, injection volume, patient metabolism, and facial movement at the treated site. Published research on HA fillers as a class indicates most adverse events are limited to mild, temporary injection-site reactions, with serious complications remaining uncommon when proper technique is followed [1].

Best Revolax® Products — What to Order and Where to Buy Revolax® Wholesale

The range covers the brand’s full treatment-depth spectrum, from entry-level superficial correction through to deep structural contouring. Whether a practice starts by choosing to buy Revolax® Fine with lidocaine or moves straight to Sub-Q, the underlying gel chemistry is the same across all three grades.

Revolax® Fine with Lidocaine is the entry formulation for superficial treatment, with lidocaine included to improve patient comfort during intradermal procedures. It is most commonly applied to fine lines in the glabellar, periorbital, and neck regions, where precise, low-volume placement is required and the built-in anesthetic reduces discomfort from repeated needle passes. Many clinics keep this variant as their default for first-time filler patients in these areas. Revolax® Fine without Lidocaine offers an identical rheological profile for practitioners who prefer topical anesthetic creams or nerve blocks, and suits patients with amide-anesthetic sensitivity.

Revolax® Deep with Lidocaine is the most versatile formulation in the range, indicated for lip augmentation, nasolabial fold correction, cheek enhancement, and marionette line treatment. Lidocaine inclusion is especially valued in lip procedures, where dense sensory innervation can cause notable discomfort. Revolax® Deep without Lidocaine serves the same indications with identical rheological properties, and is selected where anesthetic preference or patient circumstance favors the plain formulation.

Revolax® Sub-Q with Lidocaine is reserved for structural contouring, injected at subcutaneous or supraperiosteal depth for chin projection, jawline sculpting, and cheekbone augmentation, where durable lift and lateral support are required. The included lidocaine improves comfort during deeper injections, particularly where topical anesthetic penetration is limited.

Administration and Injection Technique

Revolax® Fine is injected into the superficial dermis using fine-gauge needles via linear threading or serial puncture, which smooths fine lines while preventing product visibility through thin skin. Revolax® Deep is placed into the mid-to-deep dermis using fanning, cross-hatching, or bolus injection, with volume adjusted to the required correction. Revolax® Sub-Q is administered into the subcutaneous or supraperiosteal plane, commonly using a cannula, to support even distribution, provide structural lift, and lower vascular risk [2].

Across all three grades, aspiration is recommended in high-risk anatomical zones but must not be relied on as the sole indicator of vascular safety. In alignment with class-level HA complication management [3], hyaluronidase should always be immediately available to address suspected vascular occlusion. Patient aftercare is uniform across the range: for 24 to 48 hours post-injection, patients should avoid excessive heat such as saunas and hot tubs, direct ultraviolet exposure, and strenuous physical activity. Practitioners should verify any product-specific aftercare notes in the current Revolax® IFU before patient discharge.

Regulatory Status and Market Availability

Revolax® carries CE marking for use in the European Union and United Kingdom as a Class III medical device, and is approved by South Korea’s MFDS, the regulatory authority responsible for medical devices in that market. Together these reflect independent regulatory review in two of the markets practitioners most commonly reference when evaluating an imported HA filler. Revolax® is not currently authorized for use in the United States. Local regulatory requirements should be confirmed before sourcing or administering it in any market, since classification can differ even among markets that broadly recognize CE marking.

Safety and approval status are distinct considerations. The dual CE and MFDS approvals speak to the first, since both involve independent assessment of safety and performance rather than mutual recognition of a single review.

Licensed professionals who buy Revolax® online should confirm the distributor is authorized for their market. At Medical Spa Rx, we stock the complete portfolio, including Fine, Deep, and Sub-Q in both lidocaine and non-lidocaine formulations, with volume pricing available to practices that buy Revolax® wholesale and shipping timelines confirmed at checkout.

Revolax® vs Competing Korean and European HA Fillers

Revolax® vs DERMALAX™

Both are Korean, CE-marked HA fillers with multi-grade ranges. DERMALAX™ spans Plus, Deep Plus, and Implant Plus; Revolax® spans Fine, Deep, and Sub-Q, with lidocaine options across both lines. The practical comparison is HA concentration and cross-linking density at each equivalent grade, since those determine injection resistance and how the gel holds under tissue pressure. Practices comparing the two at mid-viscosity often buy DERMALAX™ alongside a filler like Revolax® Deep rather than choosing between them.

Revolax® vs NEURAMIS®

NEURAMIS® is the closer Korean peer on product range, covering Light, Deep, Volume, and Lidocaine variants against Revolax®’s three grades. Both cover superficial through deep placement, so the comparison turns on how each brand divides that spectrum: NEURAMIS® splits the mid-range more finely, while Revolax® consolidates it into a single Deep grade. Clinics wanting narrower viscosity steps between products may buy NEURAMIS® as a complement.

Revolax® vs BELLAST®

BELLAST® is a Korean HA filler with its own cross-linking technology and published clinical data. The comparison practitioners care about is duration of correction by indication, since both brands report similar ranges but derive them from different study designs and treatment areas. Reviewing each brand’s published data against the specific indication you treat most is more useful than a general duration figure, and clinics that buy BELLAST® usually do so after that review.

Revolax® vs REVOFIL

REVOFIL is positioned for indications similar to Revolax® Deep and Sub-Q, so purity standards and cross-linking method are the meaningful differentiators rather than treatment scope. Both are monophasic cross-linked HA with residual BDDE reduced to internationally accepted levels, which means the comparison comes down to viscosity at each grade and how that translates to injection feel. Practices evaluating a structurally comparable alternative sometimes buy REVOFIL for the mid-to-deep range.

Revolax® vs INTRALINE®

INTRALINE® positions its range beyond pure HA correction into combination aesthetic formulations, which changes what the comparison covers. Against Revolax®’s three-grade depth system, INTRALINE® is better assessed indication by indication than grade by grade, since the ranges are not built on the same organizing principle. Practices building a broader treatment menu may buy INTRALINE® to cover approaches Revolax® is not designed for.

Revolax® vs PERFECTHA®

PERFECTHA® uses IPN-like cross-linking, a different method from Revolax®’s monophasic process, and reports duration in a comparable range across its viscosity grades. Cross-linking method affects gel cohesivity and degradation profile, so the technical comparison is worth making on its own terms before price enters. Practices weighing European manufacturing against a Korean system typically compare both before deciding whether to buy PERFECTHA®.

Revolax® Safety Profile — Adverse Events and Contraindications

The safety profile is broadly consistent with CE-marked, cross-linked hyaluronic acid fillers as a class [1]. Revolax® reviews from practitioners often highlight patient satisfaction with outcomes, and reviews aggregated across clinics report the same. Neither is a substitute for evaluating the product on published clinical evidence, injection technique, and individual patient suitability.

Localized injection-site reactions are the most common events: erythema, edema, tenderness, and bruising, typically mild and resolving spontaneously within one to two weeks. Delayed inflammatory nodules are uncommon but can appear weeks to months post-treatment from multifactorial triggers, and management may require anti-inflammatory therapy or hyaluronidase dissolution.

Vascular occlusion is the most clinically significant risk of any HA injection and is technique-dependent; Revolax® carries no unique vascular risk beyond the HA class standard, and practitioners must maintain rigorous training in vascular anatomy and keep hyaluronidase available. Like other HA-based formulations, Revolax® can be completely dissolved with hyaluronidase if needed, which distinguishes it from non-HA biostimulators [3].

Treatment is contraindicated for patients with hypersensitivity to hyaluronic acid or any formulation component, amide-type local anesthetic hypersensitivity in the case of lidocaine-containing variants, active skin infection or inflammation at the injection site, and during pregnancy or breastfeeding. Prior to administration, practitioners should complete a full medical history covering allergies, current medications, and previous filler procedures to support appropriate patient selection.

FAQs

What is Revolax®?

Revolax® is a CE-marked and MFDS-approved Korean HA dermal filler available in Fine, Deep, and Sub-Q formulations, each with or without lidocaine. It is a highly purified, biodegradable, monophasic cross-linked HA filler intended exclusively for licensed aesthetic practitioners.

What is Revolax® made of?

The active substance is cross-linked hyaluronic acid processed to a high-purity standard, with no animal-derived materials [4]. The acid filler contains hyaluronic acid cross-linked with BDDE to create a stable, cohesive gel, produced in three viscosity grades suited to different injection depths.

What is the difference between Revolax® Fine, Deep, and Sub-Q?

Fine is a low-viscosity formulation for superficial placement, targeting fine lines and neck wrinkles. Deep is a mid-viscosity product for lips, nasolabial folds, and cheek contouring at mid-dermal depth. Sub-Q is the high-viscosity structural formulation for chin, jaw, and cheekbone work at aesthetic implant depth [4].

How long does Revolax® last?

Revolax® Fine typically provides visible correction for 6 to 9 months, while Revolax® Deep and Sub-Q last 12 to 18 months. Duration depends on treatment area, volume used, and individual patient factors including metabolism and muscular activity at the site.

Is Revolax® FDA approved?

No. Revolax® is CE-marked for use in the EU and the UK and MFDS-approved in South Korea. It is not currently FDA-cleared for the United States market.

Is Revolax® safe?

Yes, within its approved indications and when administered by trained practitioners. Dual CE and MFDS approvals reflect independent safety and performance assessments. Adverse events are generally consistent with those associated with HA fillers, with serious events rare and predominantly technique-dependent [1].

Revolax® vs JUVÉDERM® — key differences?

Revolax® is a high-purity Korean monophasic HA filler with CE and MFDS dual approval, while JUVÉDERM® uses Allergan’s proprietary VYCROSS or Hylacross technology depending on the product. The Revolax® vs Juvederm® comparison is best made product-to-product on viscosity, cross-linking method, reported duration, and cost per syringe at the indication level rather than brand-to-brand.

RESTYLANE® vs Revolax® — how do they compare?

Both are CE-marked HA fillers with multi-grade ranges covering similar indications. The Restylane® vs Revolax® distinction is technological: RESTYLANE® uses NASHA particle technology, while Revolax® uses monophasic cross-linking. Comparison should focus on injection behavior, longevity by indication, and price per unit, with practitioners typically trialing both to assess gel feel directly.

Trying to buy Revolax® dermal filler online?

Licensed practitioners can order Revolax® through Medical Spa Rx using a secure add-to-cart checkout that supports both individual and bulk purchases in one transaction. Practices interested in buying across the full Fine, Deep, and Sub-Q range can request volume pricing and recurring order terms, and shipping details are confirmed before you complete the order.

Resources

[1] Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Plast Surg Nurs. 2015;35(1):13-32. doi:10.1097/PSN.0000000000000087. https://pubmed.ncbi.nlm.nih.gov/25730536/

[2] Lee W, Hwang SG, Oh W, Kim CY, Lee JL, Yang EJ. Practical Guidelines for Hyaluronic Acid Soft-Tissue Filler Use in Facial Rejuvenation. Dermatol Surg. 2020;46(1):41-49. doi:10.1097/DSS.0000000000001858. https://pubmed.ncbi.nlm.nih.gov/30883477/

[3] Philipp-Dormston WG. Hyaluron-Filler in der Dermatologie [Hyaluronic acid fillers in dermatology]. Hautarzt. 2018;69(6):491-509. doi:10.1007/s00105-018-4168-8

[4] Across Co., Ltd. Revolax® Fine, Deep, and Sub-Q Cross-Linked Hyaluronic Acid Gel. https://across.kr/eng/sub/sub02_03.php

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.

Related brands

ALIAXIN®

BELLAST®

BELOTERO®

CAREGEN

CROMA